Expertise in
13
conditions

Dr. Sherman D. Baker

Internal Medicine
VCU Health System Stony Point
9000 Stony Point Pkwy, 
Richmond, VA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
13
conditions
VCU Health System Stony Point
9000 Stony Point Pkwy, 
Richmond, VA 

Overview

Sherman Baker is a primary care provider, practicing in Internal Medicine in Richmond, Virginia.

Dr. Baker is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 7 clinical trials. Dr. Baker is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in VA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

VCU Health System Stony Point
9000 Stony Point Pkwy, Richmond, VA 23235
Other Locations
Virginia Commonwealth University Health System Authority
1250 E Marshall St, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
View 6 Less Clinical Trials

12 Total Publications

Spot size measurement of a deuterium-tritium dense plasma focus using neutron radiography.
Spot size measurement of a deuterium-tritium dense plasma focus using neutron radiography.
Journal: The Review of scientific instruments
Published: November 14, 2023
Similar Doctors
Expertise in
19
conditions
Dr. Velimir A. Luketic
Internal Medicine
Expertise in
19
conditions
Dr. Velimir A. Luketic
Internal Medicine

Virginia Urology Center PC

9105 Stony Point Dr, 
Richmond, VA 
 (0.3 miles away)
804-828-4060
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Velimir Luketic is a primary care provider, practicing in Internal Medicine in Richmond, Virginia. He has been practicing medicine for over 44 years. Dr. Luketic is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Primary Biliary Cholangitis, Cirrhosis, Liver Failure, Cholestasis, and Liver Transplant. Dr. Luketic is currently accepting new patients.

Expertise in
7
conditions
Dr. Wally R. Smith
Internal Medicine
Expertise in
7
conditions
Dr. Wally R. Smith
Internal Medicine

Virginia Commonwealth University Health System Authority

1250 E Marshall St, 
Richmond, VA 
 (7.5 miles away)
804-828-9690
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Wally Smith is a primary care provider, practicing in Internal Medicine in Richmond, Virginia. Dr. Smith is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Smith is currently accepting new patients.

Expertise in
48
conditions
Dr. Georgia K. Seely
Internal Medicine
Expertise in
48
conditions
Dr. Georgia K. Seely
Internal Medicine
Before you request

Dermatology Associates Of VA PC

10800 Midlothian Turnpike, Suite 309, 
Richmond, VA 
 (3.5 miles away)
804-794-2307
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Georgia Seely is a primary care provider, practicing in Internal Medicine in Richmond, Virginia. Dr. Seely is highly rated in 48 conditions, according to our data. Her clinical expertise encompasses Warts, Pustular Psoriasis, Rosacea, and Psoriasis. Dr. Seely is currently accepting new patients.

Frequently Asked Questions about Dr. Sherman D. Baker

How do I make an appointment with Dr. Sherman D. Baker?

You can book an appointment with Dr. Sherman D. Baker by calling their office at 804-327-3055. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sherman D. Baker a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sherman D. Baker is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sherman D. Baker specialize in?

While Dr. Sherman D. Baker is a Internal Medicine, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Sherman D. Baker participate in research or clinical trials?

Yes. Dr. Sherman D. Baker has published 12 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Sherman D. Baker's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sherman D. Baker accept my insurance?

Dr. Sherman D. Baker accepts most major insurance plans, including Cigna and HealthKeepers. We recommend calling the office directly at 804-327-3055 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baker's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile